Sensus Healthcare (NASDAQ:SRTS) posted its earnings results on Wednesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01, Fidelity Earnings reports. Sensus Healthcare had a negative net margin of 8.65% and a negative return on equity of 8.82%. The firm had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $7.77 million.
NASDAQ:SRTS traded down $0.21 during trading hours on Friday, reaching $3.80. 73,900 shares of the company were exchanged, compared to its average volume of 31,014. Sensus Healthcare has a twelve month low of $3.71 and a twelve month high of $9.23. The stock’s 50-day moving average is $5.73 and its 200-day moving average is $5.72. The firm has a market cap of $93.54 million, a PE ratio of -27.14 and a beta of -0.41.
Several research firms recently issued reports on SRTS. B. Riley cut shares of Sensus Healthcare from a “buy” rating to a “neutral” rating and decreased their target price for the company from $14.00 to $5.50 in a research note on Thursday. Maxim Group set a $11.00 target price on shares of Sensus Healthcare and gave the company a “buy” rating in a research note on Friday, August 9th. TheStreet upgraded shares of Sensus Healthcare from a “d+” rating to a “c-” rating in a research note on Monday, August 26th. ValuEngine cut shares of Sensus Healthcare from a “buy” rating to a “hold” rating in a research note on Thursday, October 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sensus Healthcare in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $8.30.
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
See Also: Stop Order
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.